Harada M
First Dept. of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Gan To Kagaku Ryoho. 1993 Nov;20(14):2097-107.
Autologous blood stem cell transplantation (ABSCT) has been increasingly used, as the third generation of hemopoietic stem cell transplantation next to allogeneic and autologous bone marrow transplantation (allo-BMT and ABMT), in the treatment of malignant diseases. As to the principle of treatment, ABSCT is identical to ABSCT. However, ABSCT has some advantages over ABMT as follows: 1) a rapid engraftment, 2) no requirement of general anesthesia for harvesting hemopoietic stem cells, and 3) possibility of less contamination of tumor cells. Accordingly, ABSCT will take place of ABMT in the strategy of cancer treatment and improved results will be expected.
自体血干细胞移植（ABSCT）作为继同种异体和自体骨髓移植（allo - BMT和ABMT）之后的第三代造血干细胞移植，已越来越多地用于治疗恶性疾病。就治疗原理而言，ABSCT与ABMT相同。然而，ABSCT相对于ABMT具有以下一些优势：1）植入迅速；2）采集造血干细胞时无需全身麻醉；3）肿瘤细胞污染可能性较小。因此，在癌症治疗策略中，ABSCT将取代ABMT，并有望取得更好的治疗效果。
